Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Posch

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Molecular Cancer|February 21, 2024
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanomaValentin Feichtenschlager, Linan Chen, Yixuan James Zheng, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2025
Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapyKatharina Schumann, Kai Christian Klespe, Cornelia Mauch, et al.
Research Square|December 11, 2023
The therapeutically actionable long non-coding RNA '<i>T-RECS</i>' is essential to cancer cells' survival in NRAS/MAPK-driven melanomaValentin Feichtenschlager, Linan Chen, Yixuan James Zheng, et al.
The British Journal of Dermatology|October 12, 2025
Real-world evidence on palmoplantar pustulosis: patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry studyThomas Graier, Natalie Bordag, Wolfgang Weger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 14, 2022
Adult-Onset Neurodegeneration in Nucleotide Excision Repair Disorders (NERD<sub>ND</sub> ): Time to Move Beyond the SkinIsabell Cordts, Demet Önder, Andreas Traschütz, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
Journal for Immunotherapy of Cancer|January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionAljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and SwitzerlandKatharina Schumann, Cornelia Mauch, Kai-Christian Klespe, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 15, 2025
Addiction and chronic skin diseases: A Pan-European study on prevalence, associations and patient impactStefanie Ziehfreund, Magdalena Saak, Alisa Schaal, et al.
Journal of Cancer Research and Clinical Oncology|November 21, 2020
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)Theresa Steeb, Anja Wessely, Mareike Alter, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Molecular Cancer|February 21, 2024
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanomaValentin Feichtenschlager, Linan Chen, Yixuan James Zheng, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2025
Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapyKatharina Schumann, Kai Christian Klespe, Cornelia Mauch, et al.
Research Square|December 11, 2023
The therapeutically actionable long non-coding RNA '<i>T-RECS</i>' is essential to cancer cells' survival in NRAS/MAPK-driven melanomaValentin Feichtenschlager, Linan Chen, Yixuan James Zheng, et al.
The British Journal of Dermatology|October 12, 2025
Real-world evidence on palmoplantar pustulosis: patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry studyThomas Graier, Natalie Bordag, Wolfgang Weger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 14, 2022
Adult-Onset Neurodegeneration in Nucleotide Excision Repair Disorders (NERD<sub>ND</sub> ): Time to Move Beyond the SkinIsabell Cordts, Demet Önder, Andreas Traschütz, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
Journal for Immunotherapy of Cancer|January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionAljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and SwitzerlandKatharina Schumann, Cornelia Mauch, Kai-Christian Klespe, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 15, 2025
Addiction and chronic skin diseases: A Pan-European study on prevalence, associations and patient impactStefanie Ziehfreund, Magdalena Saak, Alisa Schaal, et al.
Journal of Cancer Research and Clinical Oncology|November 21, 2020
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)Theresa Steeb, Anja Wessely, Mareike Alter, et al.
Pageof 10